We’re Speaking Out on Health Issues

NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.

Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.

Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.

Testimony of Diana Zuckerman at the Meeting of EPA’s National Environmental Justice Advisory Council on September 28, 2022

September 28, 2022: I want to comment very briefly on the PFAS recommendations, since that’s an issue we’ve worked on for years. Let me add that we are very concerned about all endocrine disrupting chemicals not just PFAS.

Testimony of Dr. Diana Zuckerman About PEPAXTO FDA Advisory Committee Meeting on September 22, 2022

We testified before the FDA Advisory Committee that Pepaxto should no longer be approved for multiple myeloma because new research shows that patients taking it died 5 months sooner than patients taking a different treatment.

NCHR Letter to Sen. Smith in Support of Women’s Health Legislation

September 22, 2022: Two bills led by Sen. Smith take critical steps to help protect access to safe and effective reproductive health care products. We at NCHR are appreciative of her work to act in the face of the many challenges presented following the Dobbs decision.

NCHR supports mandatory safety standards for sling baby carriers

September 15, 2022: We are writing to express our views on the Consumer Product Safety Commission’s adoption of a mandatory safety standard for infant sling carriers. We enthusiastically support the plan to make the current CPSC voluntary safety standards – which address product test methods, performance requirements, labeling and instructional literature –mandatory for manufacturers in […]

NCHR Comments on the CMS National Coverage Analysis of Seat Extenders for Wheelchairs

September 14, 2022: We strongly support the coverage of wheelchair seat extender systems through Medicare and encourage CMS quickly act on this decision. There are numerous direct medical benefits from the use of power seat elevation systems in power wheelchairs. Many preventable complications and secondary conditions are common among individuals who spend long periods of time unable to stand or walk, restricted to a bed, chair, or wheelchair.